Related Experiment Video
Updated: May 5, 2026
08:56
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
56.6K
Biliary atresia: will blocking inflammation tame the disease?
Kazuhiko Bessho1, Jorge A Bezerra
1Pediatric Liver Care Center and Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center and the Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio 45229-3031, USA.
Annual Review of Medicine
|January 14, 2011
Summary
Biliary atresia, a childhood liver disease, obstructs bile ducts. Early surgery helps bile flow, but immune system involvement may drive disease progression, necessitating new therapies.
Area of Science:
- Pediatric Hepatology
- Immunology
- Gastroenterology
Background:
- Biliary atresia is the leading childhood cholangiopathy.
- Complete obstruction of extrahepatic bile ducts requires prompt hepatoportoenterostomy for bile drainage restoration.
- Despite surgery, intrahepatic bile duct injury and progressive cholangiopathy can lead to cirrhosis.
Purpose of the Study:
- To explore the role of the immune system in biliary atresia pathogenesis.
- To discuss how clinical phenotyping and staging inform therapeutic strategies.
- To identify directions for developing novel therapies to halt disease progression.
Main Methods:
- Review of clinical and mechanistic data on biliary atresia.
- Analysis of immune system involvement in bile duct injury.
- Discussion of clinical trial design informed by disease staging.
Main Results:
- Immune system targeting of duct epithelium is increasingly implicated in bile duct injury.
- Disease progression varies, potentially linked to clinical forms and pathology staging.
- Clinical phenotyping and mechanistic research offer insights into therapeutic targets.
Conclusions:
- Understanding immune-mediated bile duct injury is crucial for biliary atresia management.
- Multidisciplinary approaches combining clinical and basic research are essential.
- Development of immunomodulatory therapies may offer new treatment avenues.
Related Concept Videos
01:17Chronic Bowel Disorders: Introduction
906
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
906
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:25Inflammatory Bowel Disease III: Crohn's Disease
69
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
69
01:20Cholecystitis
32
Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
32
01:21Chronic Pancreatitis II: Pathophysiology
35
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
35